Determining the cutoff based on a continuous variable to define two populations with application to vaccines

Journal of Biopharmaceutical Statistics

Volumn 23, Issue 3, 2013, Pages 662-680

  Li, Shu ^a   Parnes, Milton ^b   Chan, Ivan S F ^c  

^a Johnson and Johnson Pharmaceutical Research and Development   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Continuous variable; Cutoff point; Dichotomization; Dichotomous variable; EM method; Maximization of correlation; Numerical algorithm

Indexed keywords

CHICKENPOX VACCINE;

ALGORITHM; ARTICLE; CHICKENPOX; CONTINUOUS VARIABLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MANUFACTURE; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PARAMETERS; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ALGORITHMS; ANTIBODY FORMATION; BIOLOGICAL MARKERS; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; HUMANS; INFANT; PATIENT EDUCATION AS TOPIC; ROC CURVE; VACCINES;

EID: 84877146524     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2012.756502     Document Type: Article

References (18)

1. Anderson, P. (1984). The protective level of serum antibodies to the capsular polysaccharide of Haemophilus infuenzae type b. Journal of Infectious Diseases 140:1034.
2. Chan, I. S. F., Li, S., Matthews, H., Chan, C. Y., Vessey, S. J. R., Sadoff, J. C., Heyse, J. F. (2002). Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Statistics in Medicine 21:3411-3430.
3. Cochran, W. G., Hopkins, C. E. (1961). Some classification problems with multivariate qualitative data. Biometrics 171:10-32.
4. Crosnier, J., Jungers, P., Courouce, A. M., Laplanche, A., Benhamou, E., Degos, F., Lacour, B., Prunet, P., Cerisier, Y., Guesry, P. (1981a). Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet, February 28, 1981, 1(8218):455-459.
5. Crosnier, J., Jungers, P., Courouce, A. M., Laplanche, A., Benhamou, E., Degos, F., Lacour, B., Prunet, P., Cerisier, Y., Guesry, P. (1981b). Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet, April 11, 1981, 1(8224):797-800.
6. Dempster, A. P., Laird, N. M., Rubin, D. B. (1977). Maximum likelihood from incomplete data via the EM algorithm. Journal of the Royal Statistical Society, Series B (Methodological) 39(1):1-38.
7. Kayhty, H., Peltola, H., Karanko, V., Makela, P. H. (1983). The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenza type b. Journal of Infectious Diseases 147(6):1100.
8. Klugman, K. P., Koornhof, H. J., Robbins, J. B., Le Cam, N. N. (1996). Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14(8):435-438.
9. Kohberger, R., Xie, F. (1998). A theoretical framework for the relationship of correlates of protection, population immunogenicity, and vaccine efficacy. Paper presented at the Joint Statistical Meetings, Dallas, TX.
10. Lau, Y. L., Vessey, S. J. R., Chan, I. S. F., Lee, T. L., Huang, L. M., Lee, C. Y., Lin, T. Y., Lee, B. W., Kwan, K., Kasim, S. M., Chan, C. Y., Kaplan, K. M., Distefano, D. J., Harmon, A. L., Golie, A., Hartzel, J., Xu, J., Li, S., Matthews, H., Sadoff, J. C., Shaw, A. (2002). A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIXTM in healthy children. Vaccine 20:2942-2949.
11. Leeflang, M. M. G., Moons, K. G. M., Reitsma, J. B., Zwinderman, A. H. (2008). Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: Mechanisms, magnitude, and solutions. Clinical Chemistry 54(4):729-737.
12. Lewis, J. A. (2004). In defence of the dichotomy. Pharmaceutical Statistics 3:77-79.
13. Li, S., Chan, I. S. F., Matthews, H., Heyse, J. F., Chan, C. Y., Sadoff, J. C., Vessey, S. J. R. (2002). Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatric Infectious Diseases Journal 21:337-42.
14. Linnet, K., Brandt, E. (1986). Assessing diagnostic tests once an optimal cutoff point has been selected. Clinical Chemistry 32:1341-1346.
15. Olin, P. (1995). Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: Pertussis vaccination. Annals New York Academy of Sciences 754:273-277.
16. Stein, R. M. (2005). The Relationship between default prediction and lending profits: Integrating ROC analysis and loan pricing. Journal of Banking & Finance 29:1213-1236.
17. White, C. J., Kuter, B. J., Ngai, A., Hildebrand, C. S., Isganitis, K. L., Patterson, C. M., Capra, A., Miller, W. J., Krah, D. L., Provost, P. J. (1992). Modified cases of chickenpox after vaccination: Correlation of protection with antibody response. Pediatric Infectious Disease Journal 11:19-23.
18. Zhou, X. H., Obuchowski, N. A., Mcclish, D. (2002). Statistical Methods in Diagnostic Medicine. New York, NY: Wiley-Interscience.